💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Osimertinib Mesylate

CHEMBL3545063 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
595.7 g/mol
LogP
—
Phase
4

A mesylate salt form of osimertinib with the same therapeutic properties. A third-generation EGFR inhibitor targeting specific mutations including T790M resistance in lung cancer.

Masse moléculaire

595,7000 g/mol

TPSA

150,00 Ų

Aires thérapeutiques

Melanoma Non-Small Cell Lung Cancer Lymphoma

Mécanisme d'action

Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.CS(=O)(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H37N7O5S

                    

                    
                    

                        
HBD / HBA

                        
3 / 10

                    

                    
                    

                        
Liaisons Rotatives

                        
10

                    

                    
                    
                    

                        
Atomes Lourds

                        
42

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A mesylate salt form of osimertinib with the same therapeutic properties. A third-generation EGFR inhibitor targeting specific mutations including T790M resistance in lung cancer.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Osimertinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3545063.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 78357807.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.